Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ocular Therapeutix (OCUL) Net Income: 2013-2025

Historic Net Income for Ocular Therapeutix (OCUL) over the last 13 years, with Sep 2025 value amounting to -$68.0 million.

  • Ocular Therapeutix's Net Income fell 56.01% to -$68.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$247.3 million, marking a year-over-year decrease of 78.13%. This contributed to the annual value of -$165.1 million for FY2024, which is 83.96% down from last year.
  • Per Ocular Therapeutix's latest filing, its Net Income stood at -$68.0 million for Q3 2025, which was down 1.14% from -$67.2 million recorded in Q2 2025.
  • Ocular Therapeutix's 5-year Net Income high stood at -$19.5 million for Q1 2022, and its period low was -$68.0 million during Q3 2025.
  • In the last 3 years, Ocular Therapeutix's Net Income had a median value of -$40.8 million in 2024 and averaged -$41.2 million.
  • As far as peak fluctuations go, Ocular Therapeutix's Net Income increased by 10.95% in 2022, and later slumped by 115.51% in 2024.
  • Over the past 5 years, Ocular Therapeutix's Net Income (Quarterly) stood at -$19.7 million in 2021, then dropped by 5.38% to -$20.8 million in 2022, then fell by 9.42% to -$22.7 million in 2023, then slumped by 115.51% to -$49.0 million in 2024, then plummeted by 56.01% to -$68.0 million in 2025.
  • Its last three reported values are -$68.0 million in Q3 2025, -$67.2 million for Q2 2025, and -$63.1 million during Q1 2025.